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Background: In Europe, limited information on the use of opioids is available. 
Objectives: To assess how guideline recommendations to manage opioid-related adverse 
events were followed in cancer- and noncancer-related opioid use. 
Study Design: Analysis of health insurance data of one of the major health insurers in 
Switzerland.
Setting: All opioid claims between 2006 and 2014. 
Methods: Opioid episodes were cancer-related when cancer treatments were used within ± 
3 months of the first opioid claim. Recurrent strong episodes were defined as ≥ 2 opioid claims 
with at least one strong opioid claim. Episode duration were acute (< 90 days), subacute, or 
chronic (≥ 120 days/≥ 90 days + ≥ 10 claims). 
Results: Out of 591,633 opioid episodes 76,968 (13%) were recurrent episodes: 94% 
were noncancer related (83% in recurrent episodes) and 6% cancer related (17% recurrent). 
Chronic opioid use was observed in 55% (noncancer) and 58% (cancer) recurrent episodes. 
Recommended laxatives were used in 50% noncancer and in 67% cancer episodes. Antiemetic 
drugs were used in 54% noncancer and in 83% cancer episodes. Not recommended 
coprescription of benzodiazepines was observed in 34% recurrent noncancer and 46% cancer 
episodes.   
Limitations: No clinical information was available to assess the indication for opioid use.
Conclusions: In this study, opioids were primarily used outside the context of cancer-related 
treatment. In noncancer-related opioid use, we found a substantial higher proportion without 
recommended laxative and antiemetic medications. Coprescription of benzodiazepines may 
increase the risk for opioid overdose and was present in one-third of the noncancer episodes 
and in almost every second cancer episode. 
Key words: Pain medications, opioids, nonopioids, benzodiazepines, health insurance claims 
data, cancer pain, noncancer pain, chronic opioid use, adverse events prevention, guideline 
recommendations
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The aims of this study were 2-fold. First, we aimed 
to determine how opioids were used in a Swiss popula-
tion. Second, we assessed coprescribing of medications 
recommended or discouraged by the treatment guide-
lines. We hypothesized that the majority of strong opi-
oids were used for noncancer-related pain treatment. 
Further, we hypothesized that patients with noncancer-
related opioid use were less likely to receive treatments 
for constipation and nausea compared with patients 
with cancer pain. 
Methods 
We analyzed insurance claims data from one of 
the major health insurers in Switzerland, the Helsana 
health insurance group. The insurer covers 1.2 mil-
lion individuals (approximately one-sixth of the Swiss 
population) in all 26 cantons and maintains records of 
all health care invoices including information about 
prescribed medications reimbursed by Swiss basic man-
datory health insurance (23). The patient-level linked 
database provided information on sociodemographic 
data, health insurance status (e.g., additional private 
insurance, managed care program), prescribed drugs, 
health care use and its associated costs (inpatient, out-
patient), and the date of death.
Swiss Regulation for Opioid Prescription 
The Swiss health care system is highly decentralized 
with 26 Swiss administrative regions (cantons) respon-
sible for the planning of health services and several 
health insurance payers on the market (23). Therefore, 
no centralized opioid use registry is available. Opioids 
cannot be purchased over the counter, and for strong 
opioids a special prescription (a so-called “prescription 
for narcotic substances”) is issued on prescriptions with 
3 copies including a unique identification number. One 
copy remains with the prescribing physician, one with 
the pharmacy, and one with the insurance company. 
Although this formal procedure is aimed at reducing 
the risk of abuse, there is no central database in which 
misuse and patients with multiple parallel prescribers 
can be identified. 
Eligibility Criteria
We included all administrative claims data of adults 
who received reimbursement for at least one opioid 
prescription between January 2006 and December 
2014. We identified opioid claims using WHO pharma-
cological Anatomical Therapeutic Chemical (ATC) codes 
(24). 
Opioids are effective for the treatment of acute strong pain, cancer pain, or for symptom relief at the end of life. According to the 
World Health Organizations (WHO) pain relief ladder, 
a stepwise increase of the pain treatment intensity is 
recommended (1,2). Nonopioids are the first choice 
for mild (5-44 mm on a 100 mm Visual Analog Scale 
[VAS]) (3) to moderate pain (VAS 45-74 mm); when the 
pain is insufficiently controlled, weak opioids (e.g., 
tramadol, codeine) are recommended. Strong opioids 
(e.g., morphine, fentanyl) should be used for strong 
pain (VAS 75-100 mm) (2). Although the WHO pain 
relief ladder was developed to improve cancer pain 
treatment, the stepwise treatment approach has also 
been widely adopted for noncancer pain. 
The aim of pain treatment is to improve quality of 
life in patients. However, for noncancer pain, increasing 
evidence indicate that strong opioids are no more ef-
fective than nonopioid pain medications (4-6), but po-
tentially decrease quality of life because of side effects 
(e.g., obstipation, nausea, dizziness, and potential ad-
diction) (6-9). Further, long-term opioid use was associ-
ated with an increased risk for major trauma, addiction, 
and overdose (9). Therefore, treatment guidelines for 
chronic noncancer pain recommend the use of strong 
opioids as second-line drugs, only when alternative op-
tions result in insufficient pain control (10-12). Despite 
these recommendations, strong opioids are increas-
ingly used in chronic noncancer pain, and their use has 
reached enormous dimensions in North America (13-15) 
and in some European countries (16-18). In Switzer-
land, the use of strong opioids has more than doubled 
between 2006 and 2013, with a wide variation across 
Swiss geographic areas (18). 
Coprescribing benzodiazepines in chronic opioid 
users was associated with an increased risk for overdose 
(19) and with more pain, physical, and mental dis-
ability, and increased health care use (20). Therefore, 
the American Society of Interventional Pain Physicians 
guideline recommended avoiding the combination 
of opioids and benzodiazepines (10). The guideline 
further recommended managing opioid-related side 
effects such as constipation and nausea. In opioid users, 
constipation is common and underrecognized by health 
care professionals (21). The preventive treatment with 
laxatives is recommended when opioids are started 
before constipation is developed (22). However, it is 
unclear how physicians implement these recommen-
dations when prescribing opioids for noncancer and 
cancer pain. 
www.painphysicianjournal.com  539
Opioid Prescription and Comedication Use
Since 1999, the insurance companies reimburse 
the opioids that are prescribed with a drug substi-
tution program. We excluded opioid use for the 
substitution of opioid dependency by using specific 
reimbursement codes (TarMed position 00.0155, posi-
tions specifically assigned to substitution programs 
in pharmacies or substitution centers for buprenor-
phine, methadone, heroin, and morphine). We ex-
cluded all opioid claims from the analysis of patients 
in which substitution codes were identified at least 
once (e.g., in a patient the unique code was identi-
fied in the database in 2009, then all opioids reim-
bursed for this person were excluded). In addition, 
we excluded diamorphine using the corresponding 
ATC-code (N07BC06 Diaphin (DiaMo Narcotics GmbH, 
Thun, Switzerland)). Other specific brands are used 
within substitution programs and for pain treat-
ment: Sevre-Long (Mundipharma Medical Company, 
Basel, Switzerland) (morphine, N02AA01), Subutex 
(Indivior Schweiz AG, Baar, Switzerland) (N07BC01), 
and Temgesic (Temgesic Indivior Schweiz AG, Baar, 
Switzerland) (N02AE01, both buprenorphine), or 
L-Polamidon (Mundipharma Medical Company, Ba-
sel, Switzerland) (N07BC05) and Ketalgin (Ketalgin 
Amino AG, Gebenstorf, Switzerland ) (N07BC02, both 
methadone). These medications were included in the 
analysis as long as no code for a substitution program 
was detected. We excluded patients with recurrent 
prescriptions of Subutex sublingual (not excluded by 
the earlier defined criteria) when the daily dose was 
> 640 mg morphine equivalent assuming that Subutex 
was used within an “off-label” opioid substitution. 
Opioids and Morphine Equivalent Dose
Weak opioids included oral or rectal opioid for-
mulations with a morphine conversion factor of ≤ 0.3: 
N02AA59 (codeine and combinations), N02AX01 (tili-
dine), N02AX02 (tramadol), and N02AX06 (tapentadol). 
Strong opioids included all other opioids not defined 
as weak (see Appendix 1 for full list of ATC codes and 
opioid substances). 
We converted each reimbursement of an opioid 
medication (referred to hereafter as a “claim”) to 
a total amount of substance. To account for the dif-
ferent potencies of opioids, the morphine equivalent 
dose (MED) was calculated for each opioid (weak and 
strong) as follows: strength of opioid drug in milligrams 
per unit x quantity of units per reimbursed package x 
number of packages x conversion factor for morphine 
equivalents. The equianalgesic conversion factors are 
estimates and cannot account for individual variabil-
ity in genetics and pharmacokinetics. Wherever avail-
able, we used conversion factors provided by the Swiss 
Agency for Therapeutic Products (Swissmedic, agency 
comparable to the US Food and Drug Administration) 
or based on the CONSORT classification (CONsortium 
to Study Opioid Risks and Trends) (25). Further, we 
consulted the literature relevant to the topic and a 
clinical pharmacologist. We calculated the morphine 
equivalent dose per claim (single claim) or episode 
(multiple claims) by dividing the total MED dose by 
the number of days between each prescription (21).
The MED calculation for patches was assumed 
that one patch delivers opioids over a time provided 
by the manufacturer. For example, fentanyl patches 
deliver the dispensed (and bioavailable) micrograms 
per hour over 72 hours. The calculation of the total 
bioavailable MED dose in milligrams equals (mcg/hour 
[according to the package reimbursed] x 72 hours x 
number of patches per package x number of packages 
reimbursed x 100 [fentanyl conversion factor])/1,000. 
The total MED in milligrams for one package contain-
ing 10 fentanyl patches that each delivers 12 mcg per 
hour is calculated as follows: 12 mcg x 72 hours x 10 
patches x 100 = 864,000 mcg/1000 = 864 mg. For trans-
dermal buprenorphine patches, the assumption is that 
one patch delivers the dispensed (and bioavailable) 
micrograms per hour over 96 hours. The total MED 
dose in milligrams equals (mcg/hour [according to the 
package reimbursed] x 96 hours x number of patches 
per package x number of packages reimbursed x 95 
[buprenorphine conversion factor])/1,000. 
Opioid Episodes  
We calculated the episode durations in days using 
the difference between the claim date of the initial 
dispensation and the run-out date of the last prescrip-
tion dispensed plus one day (25). The daily dose was 
calculated by dividing the total MED per dispensed 
package by the duration of the episode. In case of sev-
eral claims, we calculated the run-out date based on 
the average daily dose between the last 2 dispensation 
dates. In case of a single claim, we used the defined 
daily dose provided by the WHO ATC based on the as-
sumed average maintenance dose per day for a drug 
used for its main indication in adults (24). We catego-
rized opioid episodes based on the duration in acute (< 
90 days), subacute (≥ 90 to < 120 days or < 10 claims), 
and chronic (≥ 90 days and ≥ 10 claims or ≥ 120 day 
supply of opioids) (25). 
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Outcomes of Interest
The main outcome of interest was the coprescrip-
tion of medications recommended or discouraged by 
treatment guidelines in cancer- and noncancer-related 
opioids in recurrent opioid use. We further compared 
the characteristics of cancer- and noncancer-related 
opioid users. 
Definition of Cancer and Noncancer Episodes
We defined an episode to be cancer related if it 
was within 3 months before and after the start of an 
opioid treatment, and one of the prespecified ATC or 
TarMed codes for cancer disease was detected. Under-
lying malignant disease was defined using ATC codes 
for malignant disease and TarMed positions related 
to cancer-specific treatments or interventions (see Ap-
pendix 2 for the full list of definitions). Episodes were 
noncancer related in all other episodes.
Comedications 
Comedications were categorized into 3 groups 
based on the recommendations of treatment guide-
lines (11): 
• Medications not recommended by treatment 
guidelines: benzodiazepines (N05BA) and stimu-
lants (N06B).
• Medications recommended by treatment guide-
lines to treat side effects: medications for constipa-
tion (e.g., sterculia, lactulose, magnesium carbon-
ate; A06A), antiemetics (e.g., ondansetron; A04A), 
and propulsive acting drugs (e.g., metoclopramide, 
domperidone; A03F).
• Medications that may be indicative of mood dis-
orders: antidepressants (N05A), psychotic drugs 
(N06C), and medications for bipolar disorders 
(N05AN).
Definition of Comorbidities
We used an adapted version of the chronic disease 
score (CDS) (26,27) to categorize comorbidities into 
chronic infections, inflammatory disease, renal disease, 
endocrine disease, diabetes, pulmonary diseases, liver 
failure, organ transplant, neurologic disease, cardiac 
disease, hyperlipidemia, glaucoma, acid peptic disease, 
thyroid disease, and gout (details of the codes are pro-
vided in Appendix 3). The CDS has been shown to be 
associated with health care use (28,29). 
Statistical Methods
Descriptive statistics included median and inter-
quartile range (IQR) for the continuous parameters, 
and percentages for the categorical parameters. Dif-
ferences with respect to continuous variables such 
as age or dose were analyzed with a nonparametric 
analysis of variance (Kruskal–Wallis test for continu-
ous variables). The chi-square tests were used to test 
categorical variables for independency. In cases in 
which both the response and grouping variable had 2 
levels, we used the Fisher exact test. Statistical analy-
sis was performed using the computing environment 
R software (R Foundation for Statistical Computing, 
Vienna, Austria), a freely available system for statisti-
cal computation and graphics environment (https://
www.r-project.org/) (30). The following R packages 
were used: DescTools, mvtnorm, foreign, Rcpp, RD-
COMClient, and tcltk.
Ethics Approval and Consent to Participate 
This study is based on administrative deidentified 
insurance claims data handled in compliance with pri-
vacy law and regulations. According to the local ethical 
committee (ethical committee of the canton, Zürich, 
Switzerland) no institutional review board approval 
was required. The study was conducted following the 
principles of good clinical practice and in accordance 
with the Declaration of Helsinki.
Results
Between January 2006 and December 2014, we 
identified out of 2,561,558 insured persons 365,116 per-
sons with opioid claims. Overall, we analyzed 591,633 
opioid episodes (Table 1; in 66% one episode, in 34% 2 
or more episodes); 35,404 episodes (6.0%) were cancer 
related and 556,229 (94.0%) were noncancer related. 
The median age was 60.0 years (IQR 44.0-74.0), 59.9% 
were women, 19.3% had supplementary voluntary 
private insurance, and 27.3% were in a managed care 
program. Overall, the episode was acute in 81.3%, 
subacute in 2.7%, and chronic in 16.0%. In 29.1% of 
episodes strong opioids were used. Laxative drugs were 
used in 14.9%, antiemetics in 20.8%, and propulsive 
drugs in 11.3%. Benzodiazepines were used in 12.6% 
and stimulants in 0.3%.
The majority of cancer-related episodes included 
the prescription of strong opioids (61.7 vs. 27.0% in 
noncancer pain) and a higher overall MED dose was 
used (median 1,342.0 vs. 323.2 mg MED). The major-
ity of episodes were acute in cancer and noncancer 
episodes (range between 60.3% and 85.3%). Chronic 
episodes of strong opioids were observed in 35.0% of 
cancer and in 23.3% of noncancer episodes. 
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Recurrent Episodes
We identified 76,968 episodes with 
strong opioids and 2 or more reimbursed 
claims (Table 2); 17.3% were cancer-
related and 82.7% were noncancer-related 
episodes. A median of 5 claims were reim-
bursed (noncancer 5, cancer 7) and 55.4% 
were chronic episodes (noncancer 55.0%, 
cancer 57.5%). The choice of the drug 
differed between cancer and noncancer-
related episodes (Appendix 4). In noncan-
cer-related episodes, oxycodone (39.4%), 
fentanyl (32.7%), and morphine (32.9%) 
were mainly prescribed. In cancer-related 
episodes, morphine was most frequently 
used (51.7%), followed by fentanyl (45.5%), 
and oxycodone (36.5%). The proportion 
of the combination oxycodone/naloxone 
was comparable in cancer- and noncancer-
related episodes (not shown). 
Use of Guideline Recommended 
Comedications
Laxative drugs were used in 53.2% 
of the episodes (50.3% noncancer, 67.1% 
cancer-related episodes; Fig. 1), antiemetics 
in 59.2% (54.2% noncancer, 82.9% cancer 
episodes), and propulsive drugs in 39.0% 
(noncancer 33.6%, cancer episodes 64.4%).
Use of Comedications Discouraged 
by Guidelines
Benzodiazepines were used in 35.9% 
(33.9% noncancer, 45.8% cancer episodes; 
Fig. 1). Psychostimulants were infrequently 
used (noncancer 0.6%, cancer 1.1%).
Medications Indicating Mood 
Disorders
Antidepressants were used in 36.0% 
(noncancer 36.4%, cancer 33.8%; Fig. 1), 
antipsychotic medications in 15.5% (non-
cancer 15.3%, cancer 16.4%), and drugs for 
bipolar disorders in 0.3% (noncancer 0.3%, 
cancer 0.2%).
Other Comedications
Paracetamol was used in 60.1% 
(noncancer 58.7%, cancer 66.4%; Fig. 1), 
metamizole in 39.9% (noncancer 37.9%, 
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cancer 49.4%), and nonsteroi-
dal anti-inflammatory drugs 
in 22.4% (noncancer 22.4%, 
cancer 23.1%). Muscle relaxants 
were used in 14.3% (noncancer 
14.7%, cancer 12.3%). Proton 
pump inhibitors were used in 
61.2% (noncancer 58.8%, cancer 
72.6%).  
discussion
The major finding of this 
study was that in 80% of strong 
opioids prescriptions, the in-
dication was noncancer pain. 
Patients with recurrent strong 
opioid claims for noncancer 
pain were less likely to use laxa-
tive, antiemetic, and propulsive 
drugs compared with cancer 
patients. Benzodiazepines were 
coprescribed in one-third of pa-
tients with noncancer pain, and 
in almost every second cancer 
episode. Overall, one-third of 
patients with recurrent opioid 
use received antidepressants, 
and one-sixth received antipsy-
chotic medications indicating a 
mood disorder. 
Results in Light of the 
Literature
Worldwide, the use of opi-
oids increased over the last 20 
years. In North America, liberal 
opioid prescription practices 
and policies promoting opioids 
for appropriate pain manage-
ment resulted in an opioid 
epidemic (31). Although stud-
ies also showed an increased 
use of strong opioids in Europe 
(16,17,32,33), the consequences 
were less clear, and a study in 
the United Kingdom found no 
increase in opioid dependence 
despite an increased use in 
opioids (34). Many studies were 
based on consumer data (32,33) 
that did not reflect the use in clinical practice driving a debate among clini-
cians about the implications in Europe (35,36). Although in Switzerland, studies 
based on consumer data indicate the highest use internationally (37), however, 
analyses of insurance claims data indicate a much smaller increase in the use 
of strong opioids (18). The difference is mainly because consumer data also 
include opioids used within addiction substitution programs that are covered 
by compulsory insurance since the 1990s. However, a recently published study 
in the primary care setting in the United Kingdom found long-term opioid use 
to be associated with serious adverse events such as major trauma, addiction, 
and overdose (34). 
Although the American Society of Interventional Pain Physicians issued 
guidance for clinicians on the responsible, safe, and effective prescription of 
opioids for chronic noncancer pain (8), the European Pain Federation posi-
tion paper focuses more on the access to opioids and misconceptions that 
may be barriers to the appropriate opioid use (12). Effective and safe pain 
management remain a challenge. The main goal is to alleviate pain with as 
little side effects as possible. Both guidelines recommend treating potential 
side effects (e.g., constipation and nausea) and to avoid the coprescribing of 
benzodiazepines. Opioid-related constipation may not be identified by clini-
cians and is a major concern and burden to patients. An international survey 
Table 2. Use in medications recommended or discouraged by guidelines in recurrent opioid 
use.
Total Noncancer Cancer
P Value
n (%), median [IQR]
Episodes, n 76,968 63,642 (82.7) 13,326 (17.3)
Age 71.0 [56.0, 81.0] 72.0 [56.0, 82.0] 67.0 [57.0, 76.0] < 0.001  
Gender, female 48,858 (63.5) 41,699 (65.5) 7,159 (53.7) < 0.001  
Number of claims 5.0 [3.0, 14.0] 5.0 [2.0, 14.0] 7.0 [3.0, 16.0] < 0.001  
Duration type
  Acute 28,862 (37.5) 24,220 (38.1) 4,642 (34.8) < 0.001 
  Subacute 5,468 (7.1) 4,446 (7.0) 1,022 (7.7)
  Chronic 42,638 (55.4) 34,976 (55.0) 7,662 (57.5)
Recommended medications
  Laxative drugs 40,937 (53.2) 31,994 (50.3) 8,943 (67.1) < 0.001 
  Antiemetic drugs 45,595 (59.2) 34,544 (54.3) 11,051 (82.9) < 0.001 
  Propulsive drugs 29,998 (39.0) 21,417 (33.7) 8,581 (64.4) < 0.001 
  Antispasmolytic drugs 477 (0.6) 406 (0.6) 71 (0.5) 0.2 
Not recommended medications
  Benzodiazepines 27,654 (35.9) 21,548 (33.9) 6,106 (45.8) < 0.001 
  Stimulants 555 (0.7) 404 (0.6) 151 (1.1) < 0.001 
Medications for mood disorders
  Antidepressants 27,681 (36.0) 23,175 (36.4) 4,506 (33.8) < 0.001 
  Antipsychotic drugs 11,913 (15.5) 9,729 (15.3) 2,184 (16.4) 0.002 
  Drugs for bipolar disorders 217 (0.3) 194 (0.3) 23 (0.2) 0.007 
The Kruskal–Wallis test was used for the comparison of continuous variables, and the chi-square 
test was used for categorical variables.
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found in patients using opioids for chronic noncancer 
pain, almost 60% had straining bowl movements that 
affected their quality of life (38). In a cohort study of 
chronic opioid users, 82% reported gastrointestinal 
symptoms equally severe in intensity as their pain (21). 
One-third of the patients who had seen their health 
care provider during the past month reported that 
they had not spoken about constipation and were 
not asked if they had constipation in the past month. 
Health care providers and patients did not agree on 
the presence of constipation at baseline in 40% (21). 
The study also found differences across countries on 
how health care providers discussed gastrointestinal 
side effects (in 46% in the United Kingdom, 52% in 
Canada, 64% in the United States, and 76% in Ger-
many) (21). In the current study, every second patient 
with recurrent strong opioid use was never prescribed 
a laxative, indicating that the uptake of the guideline 
recommendations remains particularly low in patients 
with noncancer pain.
Therefore, education of physicians treating pain 
may be necessary to improve the management of opi-
oid use in clinical practice. This is particularly relevant 
because long-term opioid use has been found to in-
crease the all-cause mortality (39), and the concomitant 
use of benzodiazepines increased the risk for opioid 
overdose (19). According to our study, one-third of 
patients with recurrent opioid claims may be at an in-
creased risk for an opioid overdose due to concomitant 
benzodiazepine use. 
Strengths and Limitations
The major strength of this study was the large 
number of opioid claims analyzed. The health insur-
Fig. 1. Coprescription of  medications in recurrent strong opioid episodes.
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ance database covers approximately one-sixth of the 
Swiss population covering all parts of the country, and 
therefore it is a quasirepresentative sample. In contrast 
to consumer data, insurances claims data allow to 
analyze prescription patterns and their association with 
patient characteristics and geographic variation. This is 
a unique way of knowing more about how opioids are 
used (40). 
The major limitation is that we were not able to 
analyze the relationship between clinical information 
(e.g., clinical diagnosis, disease severity, and symptoms) 
and opioid prescription patterns of physicians. We used 
ATC and TarMed codes to identify cancer treatments re-
lated to the opioid prescription. Although this approach 
has been used as an approximation in many studies (26-
29), we were not able to identify persons who received 
opioids for cancer-related pain but did not undergo 
specific treatments. To investigate the appropriateness 
of opioid use, further studies are needed. Further, we 
may have missed some medication use because patients 
did not send their invoices or because their annual ex-
penses did not exceed their annual deductible. Internal 
analyses of Helsana showed that ≤ 2% of costs were 
missing because persons did not send in their invoices. 
However, due to increased use of electronic invoicing, 
this effect is of decreasing importance. The database 
therefore provides an approximately complete picture 
of opioid prescriptions.
Finally, we did not have information on the use of 
hydrocodone (ATC code R05DA03), which is not covered 
by the basic insurance in Switzerland. However, hydro-
codone is in rare cases prescribed by physicians, and a 
prescription for narcotic substances is required with the 
same regulations that apply for other strong opioids.   
Implication for Research
Our study showed that the main increase is not 
related to cancer treatment. Future studies should as-
sess whether the use of strong opioids results, as this 
was the case in the United States, in an increased risk 
of overdose and deaths. Further, studies should aim to 
analyze the differences in physician practices in Europe 
that may explain wide geographic variations. In ad-
dition, future studies should quantify the amount of 
opioids in noncancer patients prescribed in end-of-life 
situations. These prescriptions are likely to be appro-
priate and should therefore be distinguished from the 
treatment of pain in nonpalliative situations.
Implication for Clinical Practice
Chronic pain is a major health care problem. Stud-
ies indicate that musculoskeletal pain are among the 
top 10 diseases resulting in pain-related disability. In 
musculoskeletal pain, several studies show that opioids 
are no more effective than nonopioid pain medica-
tions. Therefore, the prescription of pain medications 
should be based on the patient’s preferences, individual 
contraindications, and adverse effects of medications. 
In acute pain, clinicians should weight the benefit and 
harm of each pain medication individually (12). Opioids 
should be used as short as necessary when treatment 
goals are achieved. In chronic pain, prescribing opioids 
should include the definition of treatment goals that 
are monitored (10,12). In case goals are not reached 
or opioids seem to be ineffective, the pain and other 
adverse effects may improve after opioids are stopped 
(41). Opioid-related constipation may not be identified 
by clinicians (21) and is a major concern and burden to 
patients (38). Our study showed that patients receiving 
strong opioids for noncancer pain were less likely to re-
ceive laxatives, antiemetic drugs, and propulsive drugs. 
Further, clinicians should be aware of an increased risk 
for opioid overdose with the concomitant use of benzo-
diazepines, which was found in our study in one-third 
of the patients.  
conclusions
In this study, we showed that opioids were primar-
ily used outside the context of cancer treatment. In 
noncancer-related opioid use, we found a substantial 
proportion without recommended antiemetic and laxa-
tive medications. Coprescription of benzodiazepines 
may increase the risk for opioid overdose and was 
present in one-third of the noncancer episodes and in 
almost every second cancer episode.
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